These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 36225299)
1. Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies. Kawana M; Spudich JA; Ruppel KM Front Physiol; 2022; 13():975076. PubMed ID: 36225299 [TBL] [Abstract][Full Text] [Related]
2. Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics. Altibi A; Alani A; Zhao Y; Masri A Curr Cardiol Rep; 2023 Jun; 25(6):583-595. PubMed ID: 37103749 [TBL] [Abstract][Full Text] [Related]
4. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy. Hayashi T Keio J Med; 2020 Dec; 69(4):77-87. PubMed ID: 32224552 [TBL] [Abstract][Full Text] [Related]
5. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Marian AJ Circ Res; 2021 May; 128(10):1533-1553. PubMed ID: 33983830 [TBL] [Abstract][Full Text] [Related]
6. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten. Mathai S; Williams L Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022 [TBL] [Abstract][Full Text] [Related]
7. Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy. Kawana M; Sarkar SS; Sutton S; Ruppel KM; Spudich JA Sci Adv; 2017 Feb; 3(2):e1601959. PubMed ID: 28246639 [TBL] [Abstract][Full Text] [Related]
8. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. Tamargo J; Tamargo M; Caballero R Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808 [TBL] [Abstract][Full Text] [Related]
9. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca Sparrow AJ; Watkins H; Daniels MJ; Redwood C; Robinson P Am J Physiol Heart Circ Physiol; 2020 Mar; 318(3):H715-H722. PubMed ID: 32083971 [TBL] [Abstract][Full Text] [Related]
10. Prospects for remodeling the hypertrophic heart with myosin modulators. Sewanan LR; Shimada YJ Front Cardiovasc Med; 2022; 9():1051564. PubMed ID: 36330009 [TBL] [Abstract][Full Text] [Related]
11. Targeting the sarcomere in inherited cardiomyopathies. Lehman SJ; Crocini C; Leinwand LA Nat Rev Cardiol; 2022 Jun; 19(6):353-363. PubMed ID: 35304599 [TBL] [Abstract][Full Text] [Related]
12. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Tower-Rader A; Ramchand J; Nissen SE; Desai MY Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741 [TBL] [Abstract][Full Text] [Related]
13. Molecular basis of force-pCa relation in Yuan CC; Kazmierczak K; Liang J; Ma W; Irving TC; Szczesna-Cordary D Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35177471 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Dong T; Nissen S; Ospina S; Desai MY Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857 [TBL] [Abstract][Full Text] [Related]
15. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217 [TBL] [Abstract][Full Text] [Related]
16. Mavacamten decreases maximal force and Ca Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957 [TBL] [Abstract][Full Text] [Related]
17. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Marian AJ; Braunwald E Circ Res; 2017 Sep; 121(7):749-770. PubMed ID: 28912181 [TBL] [Abstract][Full Text] [Related]
18. The genetic basis of hypertrophic cardiomyopathy in cats and humans. Kittleson MD; Meurs KM; Harris SP J Vet Cardiol; 2015 Dec; 17 Suppl 1(Suppl 1):S53-73. PubMed ID: 26776594 [TBL] [Abstract][Full Text] [Related]
19. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D; Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100 [TBL] [Abstract][Full Text] [Related]
20. Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. Alsulami K; Marston S Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]